Advertisement

Product › Details
AMT-130 (Huntington’s disease gene therapy, Uniqure)
![]() |
Next higher product group | gene therapy_o |
![]() |
Status | 2016-05-31 development pp existent |
![]() |
Organisation | Uniqure N.V. (Nasdaq: QURE) |
Group | Uniqure (Group) | |
Record changed: 2024-06-07 |
Advertisement

More documents for AMT-130 (Huntington’s disease gene therapy, Uniqure)
- [1] Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam....
- [2] Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
- [3] Uniqure N.V.. (10/28/19). "Press Release: Uniqure Announces Third Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
- [4] Uniqure N.V.. (8/20/19). "Press Release: Uniqure Announces Leadership Promotions and Executive Transition". Lexington, MA & Amsterdam....
- [5] Uniqure N.V.. (4/29/19). "Press Release: Uniqure Announces First Quarter 2019 Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
- [6] Uniqure N.V.. (4/8/19). "Press Release: Uniqure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease". Lexington, MA & Amsterdam....
- [7] Uniqure N.V.. (2/28/19). "Press Release: Uniqure Announces 2018 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....
- [8] Uniqure N.V.. (1/22/19). "Press Release: Uniqure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease". Lexington, MA & Amsterdam....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top